报告期内，公司经营业绩受以下因素综合影响：(1)医保控费政策持续深化，核心产品安佳因?多次降 价，公司整体营业收入较上年同期降幅明显；(2)为推进新获批产品的市场准入与渠道建设，公司阶段 性加大商业化投入，销售费用有所增长；(3)公司持续推进多管线并行研发，多个项目处于临床研究中 后期，研发投入保持高位，对当期利润产生影响，2025年公司将由盈转亏。 格隆汇2月27日丨神州细胞(688520.SH)发布2025年度业绩快报，报告期内，公司实现营业总收入15.60亿 元，同比减少37.91%；实现归属于母公司所有者的净利润-55,329.37万元，归属于母公司所有者的扣除 非经常性损益的净利润-53,639.05万元，较上年同期相比由盈转亏。 ...

Core Viewpoint - The company, Da An Gene (002030), indicated that its 2025 annual performance forecast is based on preliminary calculations by the finance department, with performance fluctuations influenced by multiple factors including centralized procurement and healthcare cost control policies, as well as changes in the external macroeconomic environment [1] Financial Performance - The company is taking measures to address operational challenges by focusing on sustainable development and maximizing shareholder interests, which includes implementing cost-saving initiatives and enhancing operational efficiency [1] - The company has recognized impairment indicators for certain assets and has made provisions for asset impairment to solidify asset quality [1] - Final financial data will be disclosed in the officially audited 2025 annual report [1]

Core Viewpoint - The company DaAn Gene announced an expected net profit attributable to shareholders for 2025 to be between -865 million yuan and -607 million yuan, compared to -925 million yuan in the same period last year, indicating a slight improvement in losses [1][4]. Financial Summary - The projected net profit attributable to shareholders for 2025 is between -865 million yuan and -607 million yuan, while the previous year's figure was -925 million yuan [2][5]. - The net profit after deducting non-recurring gains and losses is expected to be between -938 million yuan and -658 million yuan, compared to -823 million yuan in the same period last year [2][5]. - Basic earnings per share are projected to be between -0.62 yuan and -0.43 yuan, compared to -0.66 yuan in the previous year [2][5]. - For the first three quarters of 2025, the company reported revenue of 504 million yuan and a net profit attributable to shareholders of -142 million yuan, with a significant decline expected in the fourth quarter [2][5]. Reasons for Performance Changes - The decrease in operating revenue is attributed to market demand, the implementation of centralized procurement policies, and an increase in the VAT rate on self-produced reagent products to 13%. Despite efforts to enhance operational efficiency, fixed costs have led to a negative impact on gross profit, resulting in operational losses for the year [3][6]. - The performance of joint ventures improved compared to the previous year, leading to an increase in investment income recognized by the company, which positively affected the net profit attributable to shareholders [3][6]. - The company has strengthened the collection of historical accounts receivable, resulting in a decrease in the provision for credit impairment losses compared to the previous year. However, the company also conducted a comprehensive review of various assets and recognized impairment losses on assets showing signs of impairment, which increased compared to the previous year [3][6]. - The fair value of other non-current financial assets increased, contributing to a rise in net profit attributable to shareholders, with this non-recurring gain before tax increasing by approximately 180 million yuan compared to the previous year [3][6].

Core Viewpoint - Shenzhou Cell (688520) is expected to report a net loss attributable to shareholders of the parent company between -580 million yuan and -520 million yuan for 2025, a significant decline from a net profit of 112 million yuan in the same period last year, indicating a shift from profit to loss due to industry healthcare cost control policies and price reductions of its core product Anjiah [2] Group 1 - The company's core product sales revenue has significantly decreased, leading to an overall decline in operating income compared to the same period last year [2] - The ongoing deepening of healthcare cost control policies in the industry has adversely affected the company's financial performance [2] - The price reductions of the core product Anjiah have contributed to the decline in sales revenue [2]

股票简称：华人健康 股票代码：301408 安徽华人健康医药股份有限公司 （Anhui Huaren Health Pharmaceutical Co., Ltd.） （合肥市包河工业区上海路 18 号） 首次公开发行股票并在创业板上市 之 上市公告书 保荐机构（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 2023 年 2 月 1 特别提示 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书相同。 2 第一节 重要声明与提示 一、本次发行的基本情况 本公司及全体董事、监事、高级管理人员保证上市公告书的真实性、准确性、 完整性，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依法承 担法律责任。 深圳证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。 本公司提醒广大投资者认真阅读刊载于巨潮资讯网（www.cninfo.com.cn）； 中证网（www. ...